PRTC vs. BVXP, HVO, OXB, AVCT, GNS, ONT, UPR, AMS, CRW, and MXCT
Should you be buying PureTech Health stock or one of its competitors? The main competitors of PureTech Health include Bioventix (BVXP), hVIVO (HVO), Oxford Biomedica (OXB), Avacta Group (AVCT), Genus (GNS), Oxford Nanopore Technologies (ONT), Uniphar (UPR), Advanced Medical Solutions Group (AMS), Craneware (CRW), and MaxCyte (MXCT). These companies are all part of the "medical" sector.
PureTech Health (LON:PRTC) and Bioventix (LON:BVXP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.
PureTech Health has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, Bioventix has a beta of 0.38, suggesting that its share price is 62% less volatile than the S&P 500.
PureTech Health received 437 more outperform votes than Bioventix when rated by MarketBeat users. Likewise, 86.58% of users gave PureTech Health an outperform vote while only 52.87% of users gave Bioventix an outperform vote.
Bioventix has a net margin of 65.32% compared to PureTech Health's net margin of 0.00%. Bioventix's return on equity of 70.11% beat PureTech Health's return on equity.
In the previous week, Bioventix had 3 more articles in the media than PureTech Health. MarketBeat recorded 4 mentions for Bioventix and 1 mentions for PureTech Health. Bioventix's average media sentiment score of 0.04 beat PureTech Health's score of 0.00 indicating that Bioventix is being referred to more favorably in the news media.
Bioventix has higher revenue and earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.
80.3% of PureTech Health shares are owned by institutional investors. Comparatively, 65.5% of Bioventix shares are owned by institutional investors. 14.8% of PureTech Health shares are owned by company insiders. Comparatively, 8.1% of Bioventix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Bioventix beats PureTech Health on 9 of the 15 factors compared between the two stocks.
Get PureTech Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRTC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
PureTech Health Competitors List
Related Companies and Tools